PARIS--(BUSINESS WIRE)--Regulatory News: Acticor Biotech (Paris:ALACT), a clinical stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, today ...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies, today ...

Insider got exclusive data on the highest-paid CEOs in the pharma and biotech industries in 2021. The research firm MyLogIQ identified 15 CEOs that made at least $25 million last year. These leaders ...

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

2021 saw a rush of biotechs heading for the public markets, including companies seeking an initial public offering before ever producing a shred of clinical evidence. And they paid for it. Biotech ...

The Nasdaq Biotechnology Index (NBI™) was launched on Nov. 1, 1993, when the biotech industry was still in its relative infancy and prone to heightened volatility. Ten years later, the index tracked ...

Welcome to The TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+ column where it gets its name. Want it in your inbox every Saturday? Sign up here.

Even a second year of business interruptions caused by the COVID-19 pandemic couldn’t slow North Carolina’s bioscience juggernaut in 2021. Nineteen major expansions, relocations or new facilities ...

Despite the success of COVID vaccines and medicines, the biotech sector underperformed the broader market in 2021. The Medical-Biomedical and Genetics industry declined 21.6% in 2021 against the S&P ...

Initial public offerings by biotechnology companies are slowing after two record-setting years as the poor performance of some recent IPOs combined with economic and geopolitical uncertainties have ...

Cory has been a professional trader for two decades. In addition to trading and investing he's widely published and coaches individual clients on the finer points of gaining an edge in the market.